Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A, Falo C, Fernandez-Gonzalez S, Laplana M, Gil-Gil M, Soler-Monso T, Martinez-Perez E, Calvo I, Calpelo H, Bajen MT, Benitez A, Ortega R, Petit A, Guma A, Campos M, Stradella A, Lopez-Ojeda A, Ponce J, Pla MJ, Pernas S. Garcia-Tejedor A, et al. Breast Cancer Res Treat. 2023 Jun;199(3):445-456. doi: 10.1007/s10549-023-06926-y. Epub 2023 Apr 12. Breast Cancer Res Treat. 2023. PMID: 37043108
Interaction of the C-terminal domain of the histone H1 with DNA.
Rodriguez AT, Fernandez BA, García Tejedor AJ, Morán F, Suau P, Montero F. Rodriguez AT, et al. Biochem Pharmacol. 1988 May 1;37(9):1841-2. doi: 10.1016/0006-2952(88)90473-x. Biochem Pharmacol. 1988. PMID: 3377849 No abstract available.
Removal of the internal mammary sentinel node in breast cancer.
Domènech-Vilardell A, Bajén MT, Benítez AM, Ricart Y, Mora J, Rodríguez-Bel L, García-Tejedor A, Climent J, López-Ojeda A, Urruticoechea A, Martín-Comín J. Domènech-Vilardell A, et al. Nucl Med Commun. 2009 Dec;30(12):962-70. doi: 10.1097/MNM.0b013e328330addf. Nucl Med Commun. 2009. PMID: 19696690
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR. Pernas S, et al. Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8. Breast Cancer Res Treat. 2012. PMID: 22772380 Clinical Trial.
58 results